

Bora Pharmaceuticals Reports Consolidated Revenue of NT\$1.80 Billion in July

保瑞公告 7 月自結合併營收新台幣 18 億 0 仟萬元

Taipei, Taiwan, August 7, 2025 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”) announced that its consolidated revenues for July 2025 reached NT\$1.80 billion, an increase of 4.5% compared to same period last year. Year-to-date revenues grew 22.9%. Weaker USD continues to have an impact of roughly NT\$150 million.

台北，台灣，2025 年 8 月 7 日 – 保瑞藥業（以下簡稱「保瑞」，股票代碼：6472）今日公告 7 月自結合併營收為新台幣 18 億 0 仟萬元，較去年同期增長 4.5%，然累計營收年增 22.9%；匯率對營收仍有約新台幣一億五千萬元之影響。

Pharma Sales continues to perform, led by the vigabatrin franchise as market share acceleration continues. The **CDMO** segment stabilized during the month, with revenue rising over 20% from June, an indication that the transitional integration phase is now behind us

全球銷售業務表現穩健，主要受惠於 vigabatrin 三劑型的總體市佔持續擴張；CDMO 業務亦渡過了整併過渡期、重回成長曲線，較六月增超過二成。

About Bora:

Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success "certain," Bora sets new standards in the pharmaceutical and CDMO industries.

For more, please visit:

<https://www.bora-corp.com>

<https://www.boracorpcdm.com>

關於保瑞：

保瑞藥業股份有限公司（股票代碼：6472）成立於2007年，是一家領先的製藥服務公司，自成立伊始即秉持「為全世界健康貢獻力量」的願景與目標。保瑞以整合 CDMO（委託開發與製造服務）與藥物開發銷售的「雙引擎」商業模式，協助製藥與生技合作夥伴優化產品開發流程、加速上市時程、擴大供應規模以滿足全球患者的需求。公司亦專注於美國的利基市場及罕見疾病領域，致力於透過拓展銷售通路實力提升患者的生活品質。



透過持續投資人才、生產與銷售及進入生物製劑業務領域，保瑞不斷推動業務升級與永續發展。我們以Making Success More Certain為使命，專注高品質、高效率與可靠性，在製藥及 CDMO 領域樹立新標杆。

請造訪：

企業網站 <https://www.bora-corp.com>

CDMO 網站 <https://www.boracorpcdmo.com>

Investor/Media enquiries 新聞聯繫人：

Nadiya Chen, Investor Relations 投資人關係 陳荻雅

+886 2 790-1555 Ext. 9108

Email : Nadiya.Chen@bora-corp.com